New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Gonadorelin

Pancragen vs Gonadorelin

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Sexual Health & LibidoAnti-Aging & Longevity
Gonadorelin
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
Admin Route
SubQ, Oral
SubQ, Intranasal
Research
Typical Dose
10 mg per day
100 mcg
Frequency
Daily for 10–30 days
Twice daily (every 12 hours)
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Maintains testicular size during TRT
  • Preserves fertility and sperm production during testosterone use
  • Stimulates endogenous LH/FSH production
  • Maintains HPG axis function during exogenous hormone use
  • Used for HCG-free TRT protocols
  • Helps restart natural testosterone production (PCT)
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Injection site reactions
  • Headache
  • Nausea at initiation
  • Tachycardia (rare)
  • +1 more
Stacks With